Formulation

With approximately 80 percent of new drugs suffering from poor solubility and bioavailability, understanding solid form is more important than ever.

High-throughput excipient discovery looks set to boost oral bioavailability.

Pfizer researchers share the story behind the first JAK inhibitor for rheumatoid arthritis

What are biosynthetic cannabinoids? And what do they mean for pharma?

How unravelling the complex chemistry of the cannabis plant can lead to new medicines

What's causing pharma's fascination with cannabinoids and cannabis?

How easy will it be to bring a new solid oral dosage form to market?

How controlled release can lead to better compliance.

Can hot-melt coating reduced processing times and costs, and improve taste?

John Lambert talks antibody-drug conjugates and his involvement with Kadcyla.